Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non Operating Income (2016 - 2026)

Insight Molecular Diagnostics' Non Operating Income history spans 6 years, with the latest figure at $480000.0 for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 277.78% to $480000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $902000.0, a 11375.0% increase, with the full-year FY2025 number at $902000.0, up 11375.0% from a year prior.
  • Non Operating Income hit $480000.0 in Q4 2025 for Insight Molecular Diagnostics, up from $194000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for IMDX hit a ceiling of $1.3 million in Q2 2021 and a floor of -$369000.0 in Q4 2022.
  • Historically, Non Operating Income has averaged $105250.0 across 5 years, with a median of $81000.0 in 2022.
  • Biggest five-year swings in Non Operating Income: skyrocketed 875.0% in 2022 and later plummeted 273.08% in 2024.
  • Tracing IMDX's Non Operating Income over 5 years: stood at -$108000.0 in 2021, then crashed by 241.67% to -$369000.0 in 2022, then surged by 142.28% to $156000.0 in 2023, then plummeted by 273.08% to -$270000.0 in 2024, then surged by 277.78% to $480000.0 in 2025.
  • Business Quant data shows Non Operating Income for IMDX at $480000.0 in Q4 2025, $194000.0 in Q3 2025, and $100000.0 in Q2 2025.